☆ 4.6 Article

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial

EUROPEAN UROLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Medicine, General & Internal

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer

Anis Gasmi et al.

Summary: Deregulation of the PI3K-Akt-mTOR pathway is crucial in the development and progression of various cancers. In prostate cancer, PTEN loss of function is believed to be the main driver. Despite the challenges in developing selective Akt inhibitors, recent phase II and III clinical trials have shown promising outcomes with Ipatasertib and Capivasertib in combination with androgen deprivation therapies for patients with metastatic castration-resistant prostate cancer and PTEN loss. Ongoing trials are currently evaluating different combinations of Akt inhibitors at different stages of prostate cancer.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Urology & Nephrology

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology

Philipp Nuhn et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

Simon J. Crabb et al.

INVESTIGATIONAL NEW DRUGS (2017)

Add to Collection

Article Medicine, General & Internal

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

N. D. James et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer

Zhi Liu et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2015)

Add to Collection

Article Medicine, General & Internal

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

DP Petrylak et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

Article Medicine, General & Internal

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

IF Tannock et al.

NEW ENGLAND JOURNAL OF MEDICINE (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.